Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2011 Jun 2;31(8):1805–1813. doi: 10.1161/ATVBAHA.111.226902

Figure 4.

Figure 4

A) Endothelium-dependent vasorelaxation tested in isolated mouse aortic rings from non-diabetic and diabetic apoE−/− (n=4 and 5, respectively), apoE−/−hAR+ (n = 4 and 6, respectively) sacrificed at 14 weeks of age. Relaxation is reported as percent of initial phenylephrine precontraction. Comparisons were conducted among groups for each agonist dose. *P < 0.05, diabetic apoE−/−hAR+ versus diabetic apoE−/− (doses > 10–6 M); **P < 0.05, non-diabetic apoE−/−hAR versus diabetic apoE−/− (doses >10–5.5 M). Murine aortic ECs from the indicated mice were subjected to Western blotting for detection of VCAM-1, MMP-2 antigen and MMP-2 activity. ECs were exposed to high glucose +/− AR inhibitor zopolrestat or siRNA against hAR for 24 hours. Similarly cells were incubated with and without zopolrestat along with oxLDL for 4 hrs. Western blotting was performed to detect VCAM-1 (B, D, H) and MMP-2 (C, E, I) followed by anti–actin IgG. (F, G) Zymography for detection of MMP-2 activity was performed.